Cargando…

Expression of the Antioxidative Enzyme Peroxiredoxin 2 in Multiple Sclerosis Lesions in Relation to Inflammation

Multiple sclerosis is a chronic inflammatory disease of the central nervous system, characterized by demyelination and axonal damage as well as neuronal degeneration. Since oxygen-derived free radicals are an important factor leading to tissue damage in inflammatory multiple sclerosis (MS) lesions,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Voigt, David, Scheidt, Uta, Derfuss, Tobias, Brück, Wolfgang, Junker, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412345/ https://www.ncbi.nlm.nih.gov/pubmed/28375164 http://dx.doi.org/10.3390/ijms18040760

Ejemplares similares

Extensive subpial cortical demyelination is specific to multiple sclerosis
por: Junker, Andreas, et al.
Publicado: (2020)

Acutely damaged axons are remyelinated in multiple sclerosis and experimental models of demyelination
por: Schultz, Verena, et al.
Publicado: (2017)

Peroxiredoxin 1 – an antioxidant enzyme in cancer
por: Ding, Chenbo, et al.
Publicado: (2016)

Multiple Roles of Peroxiredoxins in Inflammation
por: Knoops, Bernard, et al.
Publicado: (2016)

Expression of antioxidant enzymes in lesions of multiple sclerosis and its models
por: Moezzi, Dorsa, et al.
Publicado: (2022)

Personalized medicine in multiple sclerosis: hope or reality?
por: Derfuss, Tobias
Publicado: (2012)

Peroxiredoxin as a functional endogenous antioxidant enzyme in pronuclei of mouse zygotes
por: MORITA, Kohtaro, et al.
Publicado: (2018)

B Cells and Autoantibodies in Multiple Sclerosis
por: Pröbstel, Anne-Katrin, et al.
Publicado: (2015)

The monoclonal antibody GNbAC1: targeting human endogenous retroviruses in multiple sclerosis
por: Diebold, Martin, et al.
Publicado: (2019)

Antioxidants Special Issue: Peroxiredoxin 6 as a Unique Member of the Peroxiredoxin Family
por: Fisher, Aron B.
Publicado: (2019)

Defining distinct features of anti-MOG antibody associated central nervous system demyelination
por: Weber, Martin S., et al.
Publicado: (2018)

Cell type-specific Nrf2 expression in multiple sclerosis lesions
por: Licht-Mayer, Simon, et al.
Publicado: (2015)

Advances in multiple sclerosis research in 2009
por: Nessler, Stefan, et al.
Publicado: (2010)

Molecular biomarkers in multiple sclerosis
por: Ziemssen, Tjalf, et al.
Publicado: (2019)

Peroxiredoxin 6 Is a Key Antioxidant Enzyme in Modulating the Link between Glycemic and Lipogenic Metabolism
por: Arriga, Roberto, et al.
Publicado: (2019)

The antioxidant enzyme Peroxiredoxin-1 controls stroke-associated microglia against acute ischemic stroke
por: Kim, Sinai, et al.
Publicado: (2022)

Severe exacerbation of relapsing-remitting multiple sclerosis after G-CSF therapy
por: Rust, Heiko, et al.
Publicado: (2016)

BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma
por: Krumbholz, Markus, et al.
Publicado: (2005)

Optimizing treatment success in multiple sclerosis
por: Ziemssen, Tjalf, et al.
Publicado: (2015)

Aggressive multiple sclerosis (2): Treatment
por: Arrambide, Georgina, et al.
Publicado: (2020)

Differential expression of glucose-metabolizing enzymes in multiple sclerosis lesions
por: Nijland, Philip G., et al.
Publicado: (2015)

PARP-1 deregulation in multiple sclerosis
por: Meira, Maria, et al.
Publicado: (2019)

Iron Heterogeneity in Early Active Multiple Sclerosis Lesions
por: Tham, Mylyne, et al.
Publicado: (2020)

Peroxiredoxin-I Sustains Inflammation During Pancreatitis
por: Buckens, Hortense, et al.
Publicado: (2021)

Essential Roles of Peroxiredoxin IV in Inflammation and Cancer
por: Thapa, Pratik, et al.
Publicado: (2022)

Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey
por: Portaccio, Emilio, et al.
Publicado: (2021)

Peroxiredoxins: hidden players in the antioxidant defence of human spermatozoa
por: O’Flaherty, Cristian
Publicado: (2014)

Peroxiredoxin 2: An Important Element of the Antioxidant Defense of the Erythrocyte
por: Sadowska-Bartosz, Izabela, et al.
Publicado: (2023)

CNS inflammation after natalizumab therapy for multiple sclerosis: A retrospective histopathological and CSF cohort study
por: Häusler, Darius, et al.
Publicado: (2021)

Iron Is a Sensitive Biomarker for Inflammation in Multiple Sclerosis Lesions
por: Mehta, Veela, et al.
Publicado: (2013)

Central role of Th2/Tc2 lymphocytes in pattern II multiple sclerosis lesions
por: Planas, Raquel, et al.
Publicado: (2015)

Postmortem quantitative MRI disentangles histological lesion types in multiple sclerosis
por: Galbusera, Riccardo, et al.
Publicado: (2022)

Aggressive multiple sclerosis (1): Towards a definition of the phenotype
por: Iacobaeus, Ellen, et al.
Publicado: (2020)

Novel roles of peroxiredoxins in inflammation, cancer and innate immunity
por: Ishii, Tetsuro, et al.
Publicado: (2012)

Oligodendroglia in cortical multiple sclerosis lesions decrease with disease progression, but regenerate after repeated experimental demyelination
por: Rodriguez, Enrique Garea, et al.
Publicado: (2014)

Iron and neurodegeneration in the multiple sclerosis brain
por: Hametner, Simon, et al.
Publicado: (2013)

The topograpy of demyelination and neurodegeneration in the multiple sclerosis brain
por: Haider, Lukas, et al.
Publicado: (2016)

Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
por: Lorscheider, Johannes, et al.
Publicado: (2020)

Myelination in Multiple Sclerosis Lesions Is Associated with Regulation of Bone Morphogenetic Protein 4 and Its Antagonist Noggin
por: Harnisch, Kim, et al.
Publicado: (2019)

Glatiramer Acetate Treatment Normalizes Deregulated microRNA Expression in Relapsing Remitting Multiple Sclerosis
por: Waschbisch, Anne, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_3kpqgmeou6kku5g1c5a424kkao